Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq Market...
Lantern Pharma Inc. (LTRN)
Company Research
Source: Yahoo! Finance
Public Demonstrations at AACR 2026, San Diego — Booth 5054, April 17–22 DALLAS, April 14, 2026 BUSINESS WIRE )--Lantern Pharma Inc. (Nasdaq: LTRN) ("Lantern" or the "Company"), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai — the world's first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development — is now commercially live and actively onboarding subscribers. Subscriptions are available immediately at withzeta.ai , spanning introductory, academic, and commercial tiers, and represent a new, non-dilutive revenue stream for Lantern Pharma shareholders. The platform's commercial debut will be showcased through two landmark events: a private investor briefing at Nasdaq MarketSite in New York City on April 16, 2026 , and public demonstrations at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego at Boo
Show less
Read more
Impact Snapshot
Event Time:
LTRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LTRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LTRN alerts
High impacting Lantern Pharma Inc. news events
Weekly update
A roundup of the hottest topics
LTRN
News
- Emerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity [Yahoo! Finance]Yahoo! Finance
- Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added ToxicityBusiness Wire
- Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22Business Wire
- Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
- Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]Yahoo! Finance
LTRN
Earnings
- 8/13/25 - Beat
LTRN
Sec Filings
- 4/16/26 - Form SCHEDULE
- 4/10/26 - Form 8-K
- 4/3/26 - Form SCHEDULE
- LTRN's page on the SEC website